Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old

Clicks: 331
ID: 119778
1993
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Twenty-six children (aged 18-36 months) previously hospitalized for respiratory syncytial virus (RSV) infection were randomized to receive 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein or saline placebo by intramuscular injection. Serum was obtained at entry and at 1 a …
Reference Key
da1993theimmunogenicity Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tristram DA;Welliver RC;Mohar CK;Hogerman DA;Hildreth SW;Paradiso P;;
Journal The Journal of infectious diseases
Year 1993
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8418166
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male Child Infant preschool Clinical Trial Randomized Controlled Trial Antibodies r c welliver viral / analysis* respiratory syncytial viruses / immunology* viral / blood immunoglobulin g / blood hn protein* viral envelope proteins immunoglobulin a secretory / analysis viral proteins / immunology* viral vaccines / adverse effects viral vaccines / immunology* d a tristram p paradiso pmid:8418166 doi:10.1093/infdis/167.1.191 immunoglobulin e / analysis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.